284 related articles for article (PubMed ID: 33842535)
21. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.
Wei Q; Miao T; Zhang P; Jiang B; Yan H
Front Genet; 2022; 13():984575. PubMed ID: 36159963
[No Abstract] [Full Text] [Related]
22. Long Non-Coding RNA-TMPO-AS1 as ceRNA Binding to let-7c-5p Upregulates STRIP2 Expression and Predicts Poor Prognosis in Lung Adenocarcinoma.
Wang J; Yuan Y; Tang L; Zhai H; Zhang D; Duan L; Jiang X; Li C
Front Oncol; 2022; 12():921200. PubMed ID: 35774125
[TBL] [Abstract][Full Text] [Related]
23. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
24. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
Li X; Zhai S; Zhang J; Zhang D; Wang S; Wang L; Yu J
Front Oncol; 2021; 11():698465. PubMed ID: 34195096
[TBL] [Abstract][Full Text] [Related]
25. GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker.
Hu H; Wang ZW; Hu S; Xiang Y; Deng Y; Wan FJ; Zhang TC; Yang ZY; Liao XH
Oncol Rep; 2023 Aug; 50(2):. PubMed ID: 37387422
[TBL] [Abstract][Full Text] [Related]
26. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
Zhang X; Wu Z; Ma K
BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of
Wei D; Sun D; Sirera R; Afzal MZ; Leong TL; Li X; Wang Y
Transl Lung Cancer Res; 2023 Jul; 12(7):1517-1538. PubMed ID: 37577299
[TBL] [Abstract][Full Text] [Related]
28. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma.
Jiang F; Liang M; Huang X; Shi W; Wang Y
PeerJ; 2021; 9():e11697. PubMed ID: 34268011
[TBL] [Abstract][Full Text] [Related]
29. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Expression and Its Clinical Significance of the Secreted Phosphoprotein 1 in Lung Adenocarcinoma.
Guo Z; Huang J; Wang Y; Liu XP; Li W; Yao J; Li S; Hu W
Front Genet; 2020; 11():547. PubMed ID: 32595698
[TBL] [Abstract][Full Text] [Related]
31.
Zhou Y; Xue W; Meng X; Bhandari A; Zeng H; Kc R; Hirachan S; Xia E
Breast Cancer (Dove Med Press); 2024; 16():71-89. PubMed ID: 38476642
[TBL] [Abstract][Full Text] [Related]
32. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Cancer Cell Int; 2021 Apr; 21(1):219. PubMed ID: 33858449
[TBL] [Abstract][Full Text] [Related]
33. UBE2V2 promotes metastasis by regulating EMT and predicts a poor prognosis in lung adenocarcinoma.
Yang Z; Wu G; Zhao J; Shi G; Zhou J; Zhou X
Cancer Med; 2023 Oct; 12(19):19850-19865. PubMed ID: 37755128
[TBL] [Abstract][Full Text] [Related]
34. High expression of glycolysis-related
Yu H; Yu Z; Qin C; Bian T; Shi M
J Thorac Dis; 2022 Sep; 14(9):3488-3499. PubMed ID: 36245582
[TBL] [Abstract][Full Text] [Related]
35. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
36. BTN3A2 Expression Is Connected With Favorable Prognosis and High Infiltrating Immune in Lung Adenocarcinoma.
Lin Y; Zhou H; Li S
Front Genet; 2022; 13():848476. PubMed ID: 35873496
[No Abstract] [Full Text] [Related]
37. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
38. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
39.
Xu T; Xu S; Yao Y; Chen X; Zhang Q; Zhao X; Wang X; Zhu J; Liu N; Zhang J; Lin Y; Zou J
J Thorac Dis; 2022 Feb; 14(2):515-535. PubMed ID: 35280459
[TBL] [Abstract][Full Text] [Related]
40. Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma.
Wu G; Wang Q; Zhu T; Fu L; Li Z; Wu Y; Zhang C
Front Genet; 2021; 12():681277. PubMed ID: 34306024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
